We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

85 hedge funds and large institutions have $203M invested in Concert Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

401% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $224K

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

17% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 24

6% more funds holding

Funds holding: 80 → 85 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less capital invested

Capital invested by funds: $227M → $203M (-$24.5M)

Holders
85
Holders Change
+5
Holders Change %
+6.25%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
28
Reduced
24
Closed
13
Calls
$1.12M
Puts
$224K
Net Calls
+$898K
Net Calls Change
-$113K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
+$14.4M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.63M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$2.86M
4
BlackRock
BlackRock
New York
+$2.16M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.42M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$14.4M
2
EI
EAM Investors
California
-$5.93M
3
AG
Artal Group
Luxembourg
-$3.84M
4
EGI
EAM Global Investors
California
-$2.26M
5
Morgan Stanley
Morgan Stanley
New York
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Kynam Capital Management
New Jersey
$25.8M +$14.4M +2,747,308 +164%
BI
2
BVF Inc
California
$21.2M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$11.2M +$364K +69,214 +4%
NCM
4
Nantahala Capital Management
Connecticut
$10.1M -$288K -54,771 -3%
Millennium Management
5
Millennium Management
New York
$8.42M +$643K +122,227 +9%
Citadel Advisors
6
Citadel Advisors
Florida
$8.13M +$1.42M +269,873 +24%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$7.83M +$5.63M +1,069,700 +395%
Bank of America
8
Bank of America
North Carolina
$7.64M +$23.1K +4,391 +0.3%
ISL
9
Ingalls & Snyder LLC
New York
$7.57M -$182K -34,600 -3%
BlackRock
10
BlackRock
New York
$7.22M +$2.16M +410,760 +50%
PHP
11
Parkman Healthcare Partners
Connecticut
$7.03M +$347K +65,897 +6%
TCM
12
Tang Capital Management
California
$6.72M +$773K +146,983 +15%
RCM
13
RA Capital Management
Massachusetts
$6.36M – – –
SFM
14
Sphera Funds Management
Israel
$5.86M +$263K +50,000 +5%
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$4.49M -$739K -140,554 -15%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$4.4M +$651K +123,841 +20%
AIC
17
AWM Investment Company
New York
$3.89M – – –
Morgan Stanley
18
Morgan Stanley
New York
$3.45M -$1.99M -378,037 -39%
Barclays
19
Barclays
United Kingdom
$3.34M +$627K +119,236 +26%
NW
20
NewEdge Wealth
Pennsylvania
$3.2M – – –
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$3.19M +$2.86M +543,200 New
Alyeska Investment Group
22
Alyeska Investment Group
Illinois
$3.15M +$203K +38,579 +8%
Goldman Sachs
23
Goldman Sachs
New York
$3.06M +$997K +189,551 +57%
SSA
24
Schonfeld Strategic Advisors
New York
$2.94M +$1.29M +244,574 +94%
Renaissance Technologies
25
Renaissance Technologies
New York
$2.92M -$747K -142,000 -22%
1
2 3 4

CNCE Hedge Fund Activity: Q4 2022 in Review

85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2022, worth a combined $203M — down 11% from $227M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CNCE positions and 13 closed out — a net gain of 5 holders — while 28 added to existing stakes and 24 trimmed.

The largest buyer was Kynam Capital Management, adding an estimated $14.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $14.4M sold.

  • 85 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2022, up from 80 in Q3 2022.
  • Funds reported $203M of Concert Pharmaceuticals, Inc. stock for Q4 2022, down 11% quarter-over-quarter.
  • 18 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2022 and 13 closed out, a net change of +5 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2022 was Kynam Capital Management, an estimated $14.4M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2022 was Perceptive Advisors, an estimated $14.4M sold.

Based on aggregated 13F filings for Q4 2022.